The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
J Steffel, P Verhamme, TS Potpara… - European heart …, 2018 - academic.oup.com
The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …
Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines
W Ageno, AS Gallus, A Wittkowsky, M Crowther… - Chest, 2012 - Elsevier
Background The objective of this article is to summarize the published literature concerning
the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently …
the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently …
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines
J Ansell, J Hirsh, E Hylek, A Jacobson, M Crowther… - Chest, 2008 - Elsevier
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K
antagonists (VKAs) is part of the American College of Chest Physicians Evidence-Based …
antagonists (VKAs) is part of the American College of Chest Physicians Evidence-Based …
Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based …
Background High-quality anticoagulation management is required to keep these narrow
therapeutic index medications as effective and safe as possible. This article focuses on the …
therapeutic index medications as effective and safe as possible. This article focuses on the …
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised …
Executive Steering Committee on Behalf of the … - The Lancet, 2003 - Elsevier
BACKGROUND: Warfarin prevents ischaemic stroke in patients with non-valvular atrial
fibrillation, but dose adjustment, coagulation monitoring, and bleeding risk limit its use. The …
fibrillation, but dose adjustment, coagulation monitoring, and bleeding risk limit its use. The …
Non‐medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care
Background A range of health workforce strategies are needed to address health service
demands in low‐, middle‐and high‐income countries. Non‐medical prescribing involves …
demands in low‐, middle‐and high‐income countries. Non‐medical prescribing involves …
Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated
Background and Purpose—Warfarin is the most effective stroke prevention medication for
high-risk individuals with atrial fibrillation, yet it is often underused. This study examined the …
high-risk individuals with atrial fibrillation, yet it is often underused. This study examined the …
Effect of study setting on anticoagulation control: a systematic review and metaregression
C van Walraven, A Jennings, N Oake, D Fergusson… - Chest, 2006 - Elsevier
Background For patients receiving therapy with oral anticoagulants (OACs), the proportion of
time spent in the therapeutic range (ie, anticoagulation control) is strongly associated with …
time spent in the therapeutic range (ie, anticoagulation control) is strongly associated with …
Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record …
M Jones, P McEwan, CL Morgan, JR Peters… - Heart, 2005 - heart.bmj.com
Objective: To evaluate how well patients with non-valvar atrial fibrillation (NVAF) were
maintained within the recommended international normalised ratio (INR) target of 2.0–3.0 …
maintained within the recommended international normalised ratio (INR) target of 2.0–3.0 …
Home versus in‐patient treatment for deep vein thrombosis
R Othieno, E Okpo, R Forster - Cochrane Database of …, 2018 - cochranelibrary.com
Background Deep vein thrombosis (DVT) occurs when a blood clot blocks blood flow
through a vein, which can occur after surgery, after trauma, or when a person has been …
through a vein, which can occur after surgery, after trauma, or when a person has been …
